David Moadel

David Moadel

InvestorPlace Contributor

Expertise: Stocks, Options, Precious metals, Bitcoin, Altcoins

Education: Master's degree in education from the American College of Education, Bachelor's degree in education from Florida Atlantic University, Associate's degree in liberal arts from Palm Beach Community College

About David:
David Moadel is a financial writer for InvestorPlace.com. He has a master’s degree in education and has authored financial content for multiple websites.

David is also active as a social media influencer, with tens of thousands of followers on YouTube, Twitter, StockTwits, and other popular sites. David writes on topics ranging from stocks to cryptocurrencies, options, precious metals, bonds, futures, and other areas of finance.

Focusing on data rather than emotions, David is always on the lookout for new pathways to financial freedom. Count on David for wealth-building strategies and resources for investors and traders of all financial backgrounds.

You can follow David on YouTube, Twitter, StockTwits and LinkedIn.

Recent Articles

Be Patient with Fast-Crashing WiMi Hologram Cloud

By David Moadel, InvestorPlace Contributor

When the time is right, the augmented-reality holography market will grow exponentially and take WiMi Hologram Cloud stock to the next level.

Lemonade Looks Sweet, But Don’t Get an IPO Sugar High

By David Moadel, InvestorPlace Contributor

As a fascinating start-up that aims to disrupt the insurance market as we know it, Lemonade stock offers the prospect of refreshing profits.

These 5 Gambling Stocks Could Help You Hit the Jackpot

By David Moadel, InvestorPlace Contributor

Just like a trip to the casino, these five gambling stocks are both risky and exciting. Buy shares now for the post-pandemic jackpot.

Earnings Preview: Is Comcast All Bombast? Expect a Street Beat and More

By David Moadel, InvestorPlace Contributor

Tough cuts at NBCUniversal don't necessarily bode well for CMCSA stock, but the Peacock app's maiden flight was swift and far.

Vision of a Covid-19 Breakthrough Makes Sorrento Therapeutics Stock a Buy

By David Moadel, InvestorPlace Contributor

SRNE stock is an underappreciated gem as the company's recent acquisition offers significant product-pipeline expansion.

Load More